No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

No­var­tis CEO Vas Narasimhan as­sured in­vestors on Tues­day that it takes a care­ful, sys­tem­at­ic ap­proach to M&A af­ter record­ing an $800 mil­lion im­pair­ment to its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER